11-Feb-2020 - Molzym GmbH & Co. KG

Molzym is Part of Gradian Diagnostics

Gradian Diagnostics announced that Molzym GmbH & Co. KG is joining Gradian Diagnostics. Molzym will become the first acquisition, bringing a wide set of products and services due to their wealth of experience and expertise in molecular microbial analysis, and their focus on deep research and automation.

Molzym was founded in 2003 and headquarters in Bremen, Germany. They are a highly experienced 20-strong team of doctors, researchers, technicians and laboratory specialists, and their work covers solutions for molecular microbiology research and routine microbial pathogen diagnostics.

Prof. Michael Lorenz, founder of Molzym says: “I am delighted that Molzym will be joining Gradian Diagnostics. They share our values and hands-on, tailored approach to helping our customers achieve their aims. Being a leading microbial molecular diagnosis company we were keen to find trusted partners that we could collaborate with to deliver a full service, whilst also maintaining our focus. Being part of Gradian allows us to accelerate our growth and to set foot in the USA. Our customers will benefit, our staff will benefit, our current and new partners will benefit – a fantastic result all around.”

Alex Malbran, president of Gradian Diagnostics shares: “We are excited to have such an outstanding and esteemed company joining the group. Our ambition is to deliver best-in-class solutions that help hospitals and labs with the challenges and opportunities they face today and in the future. This could not be better served than with the brilliantly talented, and exceptional people at Molzym. It’s a privilege to have them on board and puts us in a position to improve molecular diagnosis for a broad range of customers.”

Gradian Diagnostics is based in Miami, USA. It is a holding company working on expanding diagnostic solutions by acquiring assets and companies with validated products around the world.

Facts, background information, dossiers
  • acquisitions
  • Molzym
  • molecular diagnostics
More about Molzym
  • News

    Seegene and Molzym partner on automated molecular sepsis diagnostics

    Seegene and Molzym announced a partnership on the automated Magicplex™ Sepsis, a new multi-pathogen screening test capable of quick and accurate identification of over 90 leading sepsis-causing pathogens. "The Magicplex Sepsis Test will be the new gold standard for performing accurate, rapi ... more

    NorDiag enters distribution and collaboration agreement with Molzym

    NorDiag has entered into two distribution agreements with German based Molzym GmbH & Co KG covering Molzym’s molecular diagnostic products. The first agreement is geographically restrained to USA and Canada, while the second agreement covers the Nordic countries. NorDiag has also entered i ... more

    Sepsis: Broad-spectrum PCR-Test receives CE-IVD approval

    SepsiTest™ is a novel PCR test for early and rapid diagnosis of sepsis. In less than four hours the broad-spectrum screening assay detects more than 345 relevant sepsis germs. Today’s conventional microbiological methods usually deliver results, on an average, only after 48 hours. SepsiTes ... more